Inotek Pharmaceuticals Corporation
Quick facts
Marketed products
- placebo BID
Placebo has no active pharmacological mechanism; it is an inert substance used as a control in clinical trials.
Phase 3 pipeline
- timolol 0.5% BID · Ophthalmology
Timolol is a non-selective beta-adrenergic receptor blocker that reduces intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow. - trabodenoson 3.0% QD · Ophthalmology
Trabodenoson is a selective adenosine A1 receptor agonist. - trabodenoson 4.5% BID · Ophthalmology
Trabodenoson is a selective adenosine receptor agonist that increases the activity of the A1 receptor. - trabodenoson 6.0% QD · Ophthalmology
Trabodenoson is a selective adenosine A1 receptor agonist.
Phase 2 pipeline
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Inotek Pharmaceuticals Corporation portfolio CI brief
- Inotek Pharmaceuticals Corporation pipeline updates RSS
Frequently asked questions about Inotek Pharmaceuticals Corporation
What are Inotek Pharmaceuticals Corporation's marketed drugs?
Top marketed products include placebo BID.
What is Inotek Pharmaceuticals Corporation's pipeline?
Inotek Pharmaceuticals Corporation has 4 drugs in Phase 3, 2 in Phase 2, 1 in Phase 1. Late-stage candidates include timolol 0.5% BID, trabodenoson 3.0% QD, trabodenoson 4.5% BID, trabodenoson 6.0% QD.
Related
- placebo BID
- Sector hub: All tracked pharma companies